Anti-precipitation small molecule pharmaceutical formulations
Embodiments of the present invention relate to formulations that provide addressing the precipitation problem of small molecules (e.g., levothyroxine, sumatriptan) at the injection site when administered in a highly concentrated formulation. In certain aspects, the formulations comprise at least one surfactant in a non-aqueous formulation that prevents small molecule precipitation and improves the bioavailability of the drug by enhancing absorption into systemic circulation..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 21. Nov. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
PRESTRELSKI STEVEN J [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-11-21, Last update posted on www.tib.eu: 2024-02-05, Last updated: 2024-02-09 |
|---|
| Patentnummer: |
CN117085022 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA01868114X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA01868114X | ||
| 003 | DE-627 | ||
| 005 | 20240209082851.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231208s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA01868114X | ||
| 035 | |a (EPA)CN117085022 | ||
| 035 | |a (EPA)62705720 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a PRESTRELSKI STEVEN J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Anti-precipitation small molecule pharmaceutical formulations |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-11-21, Last update posted on www.tib.eu: 2024-02-05, Last updated: 2024-02-09 | ||
| 520 | |a Embodiments of the present invention relate to formulations that provide addressing the precipitation problem of small molecules (e.g., levothyroxine, sumatriptan) at the injection site when administered in a highly concentrated formulation. In certain aspects, the formulations comprise at least one surfactant in a non-aqueous formulation that prevents small molecule precipitation and improves the bioavailability of the drug by enhancing absorption into systemic circulation. | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a SANDOVAL MICHAEL A |4 aut | |
| 700 | 0 | |a SLOAT BRIAN R |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 21. Nov. |
| 773 | 1 | 8 | |g year:2023 |g day:21 |g month:11 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/62705720/publication/CN117085022A1?q=CN117085022 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 21 |c 11 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 21 |c 11 | ||